Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation

Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation

Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke

EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,877

PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION

Petersen, P., GODTFREDSEN, J., Boysen, G., Andersen, E. D., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,814

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556

Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation

Gulløv, A. L., Koefoed, B. G., Petersen, P., Pedersen, T. S., Andersen, E. D., GODTFREDSEN, J., & Boysen, G. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.14.1513 · Cited by 301

A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)

Rash, A., Downes, T., Portner, R., Yeo, W. W., Morgan, N., & Channer, K. S. (2006) · Age and Ageing · doi:10.1093/ageing/afl129 · Cited by 283

Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation

Pérez-Gómez, F., Alegría, E., Berjón, J., Iriarte, J. A., Zumalde, J., Salvador, A., & Mataix, L. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.05.084 · Cited by 232

Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin

Hellemons, B. S. P., Langenberg, M., Lodder, J., Vermeer, F., Schouten, H. J. A., Lemmens, T., van Ree, J. W., & Knottnerus, J. A. (1999) · BMJ · doi:10.1136/bmj.319.7215.958 · Cited by 226

Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial Fibrillation

Morocutti, C., Amabile, G. A., Fattapposta, F., Nicolosi, A., Matteoli, S., Trappolini, M., Cataldo, G., Milanesi, G., Lavezzari, M., Pamparana, F., et al. (1997) · Stroke · doi:10.1161/01.str.28.5.1015 · Cited by 198

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418

Apixaban in patients with atrial fibrillation

Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403

New Antithrombotic Drugs

Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · CHEST Journal · doi:10.1378/chest.11-2294 · Cited by 539

2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation

Verma, A., Cairns, J. A., Mitchell, L. B., Macle, L., Stiell, I. G., Gladstone, D. J., McMurtry, M. S., Connolly, S. J., Cox, J. L., Dorian, P., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.08.001 · Cited by 478

Stroke prevention in atrial fibrillation: Past, present and future

Lip, G. Y. H., Freedman, B., Caterina, R. D., & Potpara, T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-11-0876 · Cited by 400

Antiplatelet Drugs

Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · CHEST Journal · doi:10.1378/chest.11-2293 · Cited by 389

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018

Brieger, D. B., Amerena, J. V., Attia, J., Bajorek, B. V., Chan, K. H., Connell, C., Freedman, B., Ferguson, C., Hall, T. L., Haqqani, H. M., et al. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.06.1043 · Cited by 335

Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran

Zhou, W., Schwarting, S., Illanes, S., Liesz, A., Middelhoff, M. A., Zorn, M., Bendszus, M., Heiland, S., van Ryn, J., & Veltkamp, R. C. (2011) · Stroke · doi:10.1161/strokeaha.111.624650 · Cited by 321

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Cairns, J. A., Connolly, S. J., McMurtry, S., Stephenson, M., & Talajic, M. R. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.11.007 · Cited by 285

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

Keshishian, A. V., Kamble, S., Pan, X., Mardekian, J., Horblyuk, R. V., Hamilton, M., & Lip, G. Y. H. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-05-0403 · Cited by 268

Age as a Risk Factor for Stroke in Atrial Fibrillation Patients

Marinigh, R., Lip, G. Y. H., Fiotti, N., Giansante, C., & Lane, D. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.028 · Cited by 232

Improved Detection of Silent Atrial Fibrillation Using 72-Hour Holter ECG in Patients With Ischemic Stroke: A Prospective Multicenter Cohort Study

Grond, M., Jauss, M., Hamann, G., Stark, E., Veltkamp, R., Nabavi, D., Horn, M., Weimar, C., Köhrmann, M., Wachter, R., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001884 · Cited by 229

Assessing bleeding risk in patients taking anticoagulants

Shoeb, M., & Fang, M. C. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0899-7 · Cited by 235

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients

Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., & Lipman, M. L. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016090980 · Cited by 231

The future of atrial fibrillation management: integrated care and stratified therapy

Kirchhof, P. F. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31072-3 · Cited by 182

Atrial fibrillation and the prothrombotic state: revisiting Virchow’s triad in 2020

Ding, W. Y., Gupta, D., & Lip, G. Y. H. (2020) · Heart · doi:10.1136/heartjnl-2020-316977 · Cited by 153

Secular Trends in Ischemic Stroke Subtypes and Stroke Risk Factors

Bogiatzi, C., Hackam, D. G., McLeod, A. I., & Spence, J. D. (2014) · Stroke · doi:10.1161/strokeaha.114.006536 · Cited by 145

Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation

Ogawa, S., Shinohara, Y., & Kanmuri, K. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1183 · Cited by 136

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation

Bai, Y., Deng, H., Shantsila, A., & Lip, G. Y. H. (2017) · Stroke · doi:10.1161/strokeaha.116.016275 · Cited by 128

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018

Brieger, D. B., Amerena, J. V., Attia, J., Bajorek, B. V., Chan, K. H., Connell, C., Freedman, B., Ferguson, C., Hall, T. L., Haqqani, H. M., et al. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00646 · Cited by 110

Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin

Ho, C. W., Ho, M.-H., Chan, P., Hai, J. J., Cheung, E. H.-L., Yeung, C., Lau, K. K., Chan, K., Lau, C., Lip, G. Y. H., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.006476 · Cited by 95

Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options

Lip, G. Y. H., Gelder, I. C. V., Bax, J. J., Hylek, E. M., Kääb, S., Schotten, U., Wegscheider, K., Boriani, G., Ezekowitz, M. D., Diener, H. C., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-07-0517 · Cited by 91

Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events

Hankey, G. J., & Eikelboom, J. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70038-7 · Cited by 87

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

Bahit, M. C., Lópes, R. D., WOJDYLA, D. M., Held, C., Hanna, M., Vinereanu, D., Hylek, E. M., Verheugt, F. W. A., Goto, S., Alexander, J. H., et al. (2016) · Heart · doi:10.1136/heartjnl-2016-309901 · Cited by 87

Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation

Guo, Y., Apostolakis, S. Z., Blann, A. D., Wang, H., Zhao, X., Zhang, Y., Zhang, D., Ma, J., Wang, Y., & Lip, G. Y. H. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.052 · Cited by 80

Anticoagulation Resumption After Intracerebral Hemorrhage

Li, Y., & Lip, G. Y. H. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0733-y · Cited by 73

Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: A single-center, retrospective, observational study

Jacobs, L. G., Billett, H. H., Freeman, K. D., Dinglas, C., & Jumaquio, L. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.002 · Cited by 70

2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview

Masoudi, F. A., Calkins, H. G., Kavinsky, C. J., Drozda, J. P., Gainsley, P., Slotwiner, D. J., & Turi, Z. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.028 · Cited by 69

Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients

Li, Y., Lee, S., Choi, E., & Lip, G. Y. H. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0190 · Cited by 68

How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?

Sankaranarayanan, R., Kirkwood, G. J., Visweswariah, R., & Fox, D. J. (2015) · Current Cardiology Reviews · doi:10.2174/1573403x10666140902143020 · Cited by 63

Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis

Chan, P., Huang, D., Yip, P.-S., Hai, J. J., Tse, H., Chan, T. M., Lip, G. Y. H., Lo, W.-K., & Siu, C. (2015) · EP Europace · doi:10.1093/europace/euv289 · Cited by 55

Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence

Chan, P. H., Hai, J. J., Chan, E. W., Li, W. H., Tse, H., Wong, I. C. K., Lip, G. Y. H., & Siu, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150674 · Cited by 53

Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention

Lópes, R. D., Atlas, S. J., Go, A. S., Lubitz, S. A., McManus, D. D., Dolor, R. J., Chatterjee, R., Rothberg, M. B., Rushlow, D. R., Crosson, L. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.019 · Cited by 50

Thromboembolic Prevention in Frail Elderly Patients With Atrial Fibrillation: A Practical Algorithm

Granziera, S., Cohen, A. T., Nante, G., Manzato, E., & Sergi, G. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.12.008 · Cited by 50

Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non–ST elevation myocardial infarction

Fosbøl, E. L., Wang, T. Y., Li, S., Piccini, J. P., Lópes, R. D., Shah, B. R., Mills, R. M., Klaskala, W. I., Alexander, K. P., Thomas, L. E., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.01.017 · Cited by 48

Stroke and Bleeding Risk in Atrial Fibrillation

Senoo, K., Lane, D. A., & Lip, G. Y. H. (2014) · Korean Circulation Journal · doi:10.4070/kcj.2014.44.5.281 · Cited by 46

Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated

Al-Shamkhani, W., Ayetey, H., & Lip, G. Y. H. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1457953 · Cited by 46

Oral Anticoagulation

Altiok, E., & Marx, N. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0776 · Cited by 47

2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview: A professional societal overview from the American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions

Masoudi, F. A., Calkins, H. G., Kavinsky, C. J., Slotwiner, D. J., Turi, Z. G., Drozda, J. P., & Gainsley, P. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26170 · Cited by 44

What are the costs of atrial fibrillation?

Blomstrom Lundqvist, C., Lip, G. Y. H., & Kirchhof, P. (2011) · Europace · doi:10.1093/europace/eur087 · Cited by 42

Risk of thromboembolic complications in adult congenital heart disease: A literature review

Karsenty, C., Zhao, A., Marijon, É., & Ladouceur, M. (2018) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2018.04.003 · Cited by 42

Prevalence of atrial fibrillation in intracerebral hemorrhage

Horstmann, S., Rizos, T., Jenetzky, E., Gumbinger, C., Hacke, W., & Veltkamp, R. C. (2013) · European Journal of Neurology · doi:10.1111/ene.12215 · Cited by 42

A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry

Kim, H., Kim, T., Cha, M., Lee, J., Park, J., Park, J., Kang, K., Shim, J., Uhm, J., Kim, J., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0146 · Cited by 41

Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials

Schnabel, R. B., Benezet‐Mazuecos, J., Becher, N., McIntyre, W. F., Fierenz, A., Lee, S. F., Goette, A., Atar, D., Bertaglia, E., Benz, A. P., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae596 · Cited by 43

Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome

Halbritter, K., Beyer‐Westendorf, J., Nowotny, J., Pannach, S., Kuhlisch, E., & Schellong, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12148 · Cited by 36

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban

Kirchhof, P. F., Haas, S. K., Amarenco, P., Hess, S., Lambelet, M., van Eickels, M., Turpie, A. G. G., Camm, A. J., & the XANTUS Investigators* (2020) · Journal of the American Heart Association · doi:10.1161/jaha.118.009530 · Cited by 35

Antithrombotic Treatment in Patients With Heart Failure and Associated Atrial Fibrillation and Vascular Disease

Lamberts, M., Lip, G. Y. H., Ruwald, M. H., Hansen, M. L., Özcan, C., Kristensen, S. L., Køber, L., Torp-Pedersen, C. T., & Gislason, G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.039 · Cited by 31

Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non‐valvular atrial fibrillation

Bertozzo, G., Zoppellaro, G., Granziera, S., Marigo, L., Rossi, K., Petruzzellis, F., Perissinotto, E., Manzato, E., Nante, G., & Pengo, V. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13427 · Cited by 30

Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons

Verdecchia, P., Angeli, F., Lip, G. Y. H., & Reboldi, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100478 · Cited by 28

The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey

Gattellari, M., Worthington, J. M., Zwar, N. A., & Middleton, S. (2008) · BMC Family Practice · doi:10.1186/1471-2296-9-62 · Cited by 28

Juvenile Stroke: A Practice-Oriented Overview

Schöberl, F., Ringleb, P. A., Wakili, R., Poli, S., Wollenweber, F. A., & Kellert, L. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0527 · Cited by 34

“Triple Therapy” or Triple Threat?

Francescone, S., & Halperin, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.034 · Cited by 28

Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS)

Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castellà, M., Dan, G., Dilaveris, P., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.10.022 · Cited by 34

Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation

Guo, Y., Wang, H., Zhao, X., Zhang, Y., Zhang, D., Ma, J., Wang, Y., & Lip, G. Y. H. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.12.099 · Cited by 25

Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach

Verdecchia, P., Angeli, F., Bartolini, C., Filippo, V. D., Aita, A., Giacomo, L. D., Poltronieri, C., Lip, G. Y. H., & Reboldi, G. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.971009 · Cited by 25

Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry

Lehto, M., Niiranen, J., Korhonen, P. A., Mehtälä, J., Khanfir, H., Hoti, F. J., Lassila, R., & Raatikainen, P. M. J. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4194 · Cited by 29

Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What’s next?

Marx, S., Wehling, M., & Harenberg, J. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0463 · Cited by 24

Paroxysmal atrial fibrillation in young cryptogenic ischemic stroke: A 3-week ECG Holter monitoring study

Šaňák, D., Hutyra, M., Král, M., Bártková, A., Zapletalová, J., Fedorco, M., Veverka, T., Vindiš, D., Dorňák, T., Skála, T., et al. (2015) · Biomedical Papers · doi:10.5507/bp.2015.019 · Cited by 24

Subclinical atrial fibrillation and stroke: insights from continuous monitoring by implanted cardiac electronic devices

Lau, C., Siu, C.-W., Yiu, K., Lee, K. L., Chan, Y., & Tse, H. (2015) · EP Europace · doi:10.1093/europace/euv235 · Cited by 23

Which Oral Anticoagulant for Which Atrial Fibrillation Patient: Recent Clinical Trials and Evidence-Based Choices

Cairns, J. A. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.05.010 · Cited by 22

History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

Caterina, R. D., Andersson, U., Alexander, J. H., Al‐Khatib, S. M., Bahit, M. C., Goto, S., Hanna, M., Held, C., Hohnloser, S. H., Hylek, E. M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.005 · Cited by 22

Atrial Fibrillation in Young Ischemic Stroke Patients: An Underestimated Cause?

Šaňák, D., Hutyra, M., Král, M., Bártková, A., Zapletalová, J., Fedorco, M., Veverka, T., Vindiš, D., Dorňák, T., Skála, T., et al. (2015) · European Neurology · doi:10.1159/000369793 · Cited by 22

Stroke prevention in atrial fibrillation: State of the art

Li, Y., & Lip, G. Y. H. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.057 · Cited by 21

Assessment of endothelial (dys)function in atrial fibrillation

Krishnamoorthy, S., Lim, S., & Lip, G. Y. H. (2009) · Annals of Medicine · doi:10.1080/07853890903160726 · Cited by 21

The value and limitations of new oral anticoagulant plasma level assessments

der Linden, L. R. V., Hias, J., & Vanassche, T. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab153 · Cited by 19

First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans

Neháj, F., Sokol, J., Ivanková, J., Mokáň, M., Kovář, F., Staško, J., & Mokáň, M. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617734310 · Cited by 19

2015 ACC/HRS/SCAI left atrial appendage occlusion device societal overview

Masoudi, F. A., Calkins, H. G., Kavinsky, C. J., Drozda, J. P., Gainsley, P., Slotwiner, D. J., & Turi, Z. G. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.06.034 · Cited by 18

Efficacy and Safety of Oral Anticoagulants Versus Aspirin for Patients With Atrial Fibrillation

Zhang, J., Chen, K., & Zhang, S. (2015) · Medicine · doi:10.1097/md.0000000000000409 · Cited by 18

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation

Jansson, M., Själander, S., Sjögren, V., Björck, F., Renlund, H., Norrving, B. G., & Själander, A. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02763-w · Cited by 16

A cluster-randomized controlled trial of a computerized antithrombotic risk assessment tool to optimize stroke prevention in general practice: a study protocol

Bajorek, B. V., Magin, P. J., Hilmer, S. N., & Krass, I. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-55 · Cited by 17

Nuevos anticoagulantes orales en pacientes con enfermedad renal crónica

Belmar, L., de Francisco, Á. L. M., da Silva, J. B., Espinoza, L. G., & Fresnedo, G. F. (2016) · Nefrología · doi:10.1016/j.nefro.2016.08.006 · Cited by 17

Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow‐up cohort study

McIntyre, W. F., Mendoza, P. A., Belley‐Côté, E. P., Whitlock, R. P., Um, K. J., Майстренко, Н. С., Devereaux, P. J., Conen, D., Wong, J. A., Connolly, S. J., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23053 · Cited by 15

Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study

den bosch, I. V., Bouillon, T. W., Verhamme, P. B., Vanassche, T., Jacquemin, M. G., Coemans, M., Kuypers, D. R. J., & Meijers, B. K. I. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa351 · Cited by 16

A Pint of Sweat Will Save a Gallon of Blood

Granger, C. B., & Chertow, G. M. (2014) · Circulation · doi:10.1161/circulationaha.113.007549 · Cited by 16

Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation

Jansson, M., Själander, S., Sjögren, V., Renlund, H., Norrving, B. G., & Själander, A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.11.010 · Cited by 16

Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach.

Ali, A., Bailey, C., & Abdelhafiz, A. H. (2012) · Europe PMC (PubMed Central) · Cited by 15

Gastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation control

Chan, P., Li, W., Hai, J. J., Chan, K., Tse, H., Cheung, B. M. Y., Chan, E. W., Wong, I. C. K., Leung, W. K., Hung, I. F., et al. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv032 · Cited by 15

Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2014) · Cited by 14

Atrial Appendage Thrombosis Risk Is Lower for Atrial Flutter Compared with Atrial Fibrillation

Huang, J. J., Reddy, S., Truong, T., Suryanarayana, P. G., & Alpert, J. S. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.10.041 · Cited by 14

New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures

COCCHERI, S., & Orlando, D. (2012) · Internal and Emergency Medicine · doi:10.1007/s11739-012-0886-6 · Cited by 13

Clinical trials with new oral anticoagulants

Weiss, C., & Harenberg, J. (2013) · Hämostaseologie · doi:10.5482/hamo-12-11-0021 · Cited by 13

Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies.

Bryniarski, L., Pelc-Nowicka, A., Zabojszcz, M., & Mirek-Bryniarska, E. (2009) · PubMed · Cited by 13

Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients

Joung, B. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0158 · Cited by 12

Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease

Cairns, J. A., & McMurtry, M. S. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.006 · Cited by 12

Cardiac Procedures to Prevent Stroke: Patent Foramen Ovale Closure/Left Atrial Appendage Occlusion

Freixa, X., Arzamendi, D., Tzikas, A., Noble, S., Basmadjian, A., Garceau, P., & Ibrahim, R. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.11.008 · Cited by 12

Practice Gap in Atrial Fibrillation Oral Anticoagulation Prescribing at Emergency Department Home Discharge

Kea, B., Waites, B. T., Lin, A. L., Raitt, M. H., Vinson, D. R., Ari, N., Welle, L., Sill, A. P., Button, D. A., & Sun, B. (2020) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2020.3.45135 · Cited by 12

An Update on Anticoagulation in Atrial Fibrillation

Amerena, J. V., & Ridley, D. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.05.131 · Cited by 11

Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?

Hankey, G. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328334e67b · Cited by 11

Hemorrhagic transformation and stroke recurrence in children with cardiac disease receiving antithrombotic therapy for secondary stroke prevention

Pulcine, E., Seed, M., Brandão, L. R., Slim, M., Palasamudram, S., Shroff, M. M., Moharir, M. D., deVeber, G., & Dlamini, N. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15428 · Cited by 10

Does the presence of diabetes mellitus confer an increased risk of stroke in patients with atrial fibrillation on direct oral anticoagulants? A systematic review and meta-analysis

Abdool, M., Kunutsor, S. K., Khunti, K. K., & Seidu, S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.08.038 · Cited by 10

New oral anticoagulants in patients with chronic kidney disease

Belmar, L., de Francisco, Á. L. M., da Silva, J. B., Espinoza, L. G., & Fresnedo, G. F. (2017) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2017.04.013 · Cited by 9

Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation

Zoppellaro, G., Granziera, S., Bertozzo, G., Denas, G., Marigo, L., Petruzzellis, F., Jose, S. P., Rossi, K., Nante, G., & Pengo, V. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-11-0846 · Cited by 9

Study protocol: the DESPATCH study: Delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare

Gattellari, M., Leung, D. Y., Ukoumunne, O. C., Zwar, N. A., Grimshaw, J., & Worthington, J. M. (2011) · Implementation Science · doi:10.1186/1748-5908-6-48 · Cited by 9

The pathophysiology and management of atrial fibrillation

Banner, D. (2008) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2008.3.5.29332 · Cited by 9

Warfarin

Gattellari, M., Worthington, J., & Zwar, N. A. (2008) · Stroke · doi:10.1161/strokeaha.108.527903 · Cited by 9

Anticoagulant Therapy-Induced Gallbladder Hemorrhage after Cardiac Valve Replacement

Cho, S. H., Lee, H., & Kim, H. S. (2015) · The Korean Journal of Thoracic and Cardiovascular Surgery · doi:10.5090/kjtcs.2015.48.6.432 · Cited by 8

Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation

Sideris, S. K., Archontakis, S., Latsios, G., Lazaros, G. A., Toutouzas, K. P., Tsiamis, E. G., Vavuranakis, M., Vlachopoulos, C., Gatzoulis, K. A., Tsioufis, C., et al. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170718124742 · Cited by 8

Warfarin prevails for stroke prevention in atrial fibrillation—even in octogenarians

Albers, G. W. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70227-2 · Cited by 2

Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]

Mant, J., Richards, S. H., Hobbs, R. F., Fitzmaurice, D. A., Lip, G. Y. H., Murray, E. T., Banting, M., Fletcher, K., Rahman, J. K., Allan, T. F., et al. (2003) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-3-9 · Cited by 49

Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care.

Jaffer, A. K. (2007) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.12.6.172 · Cited by 1

Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population.

Mant, J. W. F., Richards, S. H., Hobbs, R., Fitzmaurice, D. A., Lip, G. Y. H., Murray, E. T., Banting, M. V., Fletcher, K., Rahman, J., Allan, T. F., et al. (2003) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Waldo, A. L. (2008) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)79274-5 · Cited by 52